U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023年 5月 30日
Read MoreInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
2023年 5月 23日
Read MoreJournal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
2023年 4月 27日
Read MoreSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
2023年 4月 17日
Read More